Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing published clinical trial results without systematic review methodology.
PubMed 35359259 · doi:10.1007/s40257-022-00681-4
What was done
This narrative review summarizes long-term safety and efficacy data from landmark registration trials (including CheckMate 067, Keynote-006, and Keynote-001) evaluating approved first-line immune checkpoint inhibitors—ipilimumab, nivolumab, and pembrolizumab—in metastatic melanoma regardless of BRAF mutation status.
What was found
Combination therapy with ipilimumab plus nivolumab achieved a 5-year overall survival of just over 50%. A subset of patients achieved durable, long-lasting responses, but toxicity remains a critical risk, including life-threatening and life-changing adverse events. Specific quantitative data for monotherapies, response rates, and exact adverse event frequencies were not reported in the abstract.
Why it matters
It highlights that combination immune checkpoint blockade provides unprecedented 5-year survival in advanced melanoma, while emphasizing the clinical need to balance efficacy against substantial long-term toxicities when choosing regimens.
Limits
As a narrative review, it lacks systematic search methodology, formal quality scoring, or meta-analytic pooling. The abstract provides minimal quantitative data beyond a single 5-year survival percentage.
Cited by
- supports Immune checkpoint inhibitors provide roughly a 50% response or cure rate in patients with melanoma.